Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Translating the Neurobiology of Addiction Into New Treatments: Medication Assisted Recovery

493 views

Published on

Barbra J. Mason Ph.D. -
Member, RiverMend Health Scientific Advisory Board for Addiction & Psychiatry. Pearson Family Professor, Committee on the Neurobiology of Addictive Disorders
Co-Director, The Pearson Center for Alcoholism and Addiction Research.

Dr. Mason addresses the RiverMend Health Scientific Advisory Board on the biological processes that occur in the brain of addict and the recovery processes to help counter these processes.

To watch lecture visit : http://vimeo.com/100308628

For more information visit: http://www.rivermendhealth.com/scientific-advisory-board-addiction.html

Published in: Health & Medicine
  • Login to see the comments

  • Be the first to like this

Translating the Neurobiology of Addiction Into New Treatments: Medication Assisted Recovery

  1. 1. Translating the Neurobiology of Addiction Into New Treatments: Medication Assisted Recovery Barbara J. Mason, Ph.D. Pearson Family Professor, Committee on the Neurobiology of Addictive Disorders Co-Director, The Pearson Center for Alcoholism and Addiction Research SAB Malibu Beach Sept. 29 & 30, 2013
  2. 2. Source: SAMHSA National Survey on Drug Use and Health, 2010 Numbers in Thousands
  3. 3. Medication Targets in the Cycle of Alcoholism and Addiction Protracted Withdrawal Binge/ Intoxication Acute Withdrawal
  4. 4. Opioid Dependence  naltrexone (ReVia, Vivitrol): $41M **  methadone (Dolophine): $44M  buprenorphine (Suboxone) $1.2B Nicotine Dependence  varenicline (Chantix): ~$710M  nicotine patch, nicotine gum: OTC $3.4B  bupropion (Zyban): ~$550M ** Alcohol Dependence  naltrexone (ReVia, Vivitrol): $41M **  acamprosate (Campral): $81M * From: http:www.evaluatepharma.com ** Includes all indications
  5. 5. Nucleus Accumbens (Binge-intoxication) — Structure in the front bottom of the brain involved in the rewarding effects of drugs of abuse that is a key part of the binge/intoxication stage of addiction. Contains reward neurotransmitters dopamine and opioid peptides that are involved in the euphoric effects of addiction. Extended Amygdala (Withdrawal-negative affect) — A set of structures in the front middle of the brain that include the central nucleus of the amygdala, bed nucleus of the stria terminalis, and part of the nucleus accumbens. Contains brain “stress” neurotransmitter corticotropin-releasing factor that produces dysphoria during withdrawal in addiction. Prefrontal Cortex (“Craving”)— Structure in the front top of the brain involved in executive function that plays a key role in relapse to addiction. Executive function combines elements of delay in gratification and inhibition to allow healthful choices and decisions. Contains the major excitatory neurotransmitter glutamate that reawakens “craving”.
  6. 6. Existing medications • disulfiram • naltrexone • methadone • varenicline • buprenorphine Future targets • partial agonists (intoxication blockers) • drug vaccines (intoxication blockers)
  7. 7. Existing medications • methadone • nicotine patch • buprenorphine • varenicline Future targets • GABA modulators (homeostatic resetters) • CRF1 antagonists (stress reducers) • κ opioid antagonists (dysphoria reducer)
  8. 8. Existing medications • acamprosate • buproprion Future targets • GABA modulators (homeostatic resetters) • CRF1 antagonists (stress reducers) • Glutamate modulators (habit reducers)
  9. 9. Substance abuse treatment has proven efficacy, is cost effective, and has gained parity with other medical disorders for reimbursement by 3rd party payors Identify and pre-clinically validate novel targets Re-purpose available drugs and shelved investigational drugs for other indications Develop vaccines and novel routes of administration •Use human laboratory studies for proof of concept •Increase addiction medicine training programs and fellowships to expand the network of prescribers
  10. 10. Substance abuse treatment has proven efficacy, is cost effective, and has gained parity with other medical disorders for reimbursement by 3rd party payors Identify and pre-clinically validate novel targets Re-purpose available drugs and shelved investigational drugs for other indications Develop vaccines and novel routes of administration •Use human laboratory studies for proof of concept •Increase addiction medicine training programs and fellowships to expand the network of prescribers

×